Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.

Breast cancer (Tokyo, Japan) - 1 Mar 2026

Sato Riko, Kamohara Rena, Matsuo Tomohei, Sawa Aya, Okazaki Mai, Hashimoto Sachie, Iguchi-Manaka Akiko, Hara Hisato, Doki Kosuke, Mukai Yuji, Homma Masato, Ishii Ryota, Shimada Kensuke, Bando Hiroko

Abstract excerpt

BACKGROUND: Although venlafaxine has shown efficacy for hot flashes in hormone receptor–positive breast cancer, evidence in Asian women (especially premenopausal) remains limited. Hot flashes reduce endocrine therapy adherence and severity may increase with ovarian suppression. We conducted a prospective, single-arm, open-label study to evaluate the efficacy and safety of venlafaxine in tamoxifen-treated patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Tamoxifen

Share to Treatment Outcome

Share to Venlafaxine Hydrochloride

Source

Open in PubMed Open full text

Identifiers

PMID: 41642486
DOI: 10.1007/s12282-026-01828-5
PMCID: PMC12960305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial.PMID 41642486Read ↗

Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single‑arm, open‑label trialSemantic proximity Read ↗

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy.Semantic proximity Read ↗

Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.Semantic proximity Read ↗

Clinical and biomarker predictors of side effects from tamoxifen.Semantic proximity Read ↗

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.Semantic proximity Read ↗

Tamoxifen Dose Escalation in CYP2D6 Poor Metabolizer Breast Cancer Patients and Associated Side EffectsSemantic proximity Read ↗

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.Semantic proximity Read ↗

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.Semantic proximity Read ↗

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.Semantic proximity Read ↗

Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review.Semantic proximity Read ↗

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read ↗

Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.